Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study is specifically designed to determine whether the initiation of Myfortic 2 weeks
prior to transplantation will enhance the therapeutic efficacy of Simulect induction therapy
in low to moderate risk patients. Specifically, the addition of Myfortic pretransplant to
Simulect induction will be compared to standard Myfortic therapy with Thymoglobulin induction
starting at the time of transplant in kidney transplant recipients.